Skip to main content

Table 2 Tumor and lymphoid organ metrics for the pre-therapy scan (t0), post-therapy scan (t1) and rates of change (Δ)

From: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

 

t0

t1

Δ(t0)

Δ(t1)

Tumor

 MTV, ml

39.5 (7.9–284.4)

30.6 (4.9–224.6)

1.35 (0.49–2.31)

 TLG, ml

308.9 (19.1–1802.1)

132.8 (15.2–2085.9)

1.35 (0.29–3.73)

 SUVmean

7.6 (5.0–9.7)

6.2 (3.4–10.8)

0.94 (0.61–1.13)

1.08 (0.81–1.36)

 SUVmax

16.9 (9.9–24.6)

11.6 (6.9–25.9)

0.76 (0.53–1.42)

1.02 (0.67–1.53)

 V, ml

27.2 (1.5–54.2)

12.9 (2.7–129.5)

1.37 (0.71–2.09)

1.37 (0.71–2.09)

 Vtotal, ml

34.7 (4.0–219.9)

17.6 (3.4–202.7)

1.60 (0.78–2.39)

 ADCmean, × 10-3 mm2/s

0.89 (0.66–1.10)

1.01 (0.71–1.34)

1.17 (1.03–1.64)

0.92 (0.80–1.16)

Bone marrow

 SUVmean

1.8 (1.2–2.4)

1.3 (0.9–1.9)

0.79 (0.66–0.86)

 FF, %

81 (73–88)

82 (79–86)

1.01 (0.99–1.09)

 ADCmean, × 10-3 mm2/s

0.49 (0.44–0.59)

0.51 (0.40–0.57)

1.01 (0.79–1.09)

Spleen

 SUVmean

1.9 (1.7–2.2)

1.8 (1.5–2.1)

0.93 (0.79–0.99)

 V, ml

136.9 (83.1–273.7)

155.8 (93.1–261.7)

1.09 (0.99–1.21)

 ADCmean, × 10-3 mm2/s

1.04 (0.82–1.15)

0.91 (0.68–0.96)

0.91 (0.76–1.10)

  1. Median values with the IQR in parentheses. Δ(t0) corresponds to the rate of change with pre-therapy target lesion selection, while Δ(t1) corresponds to the rate of change with post-therapy target lesion selection